MiR-27a Regulates the Sensitivity of Breast Cancer Cells to Cisplatin Treatment Via BAK-SMAC/DIABLO-XIAP Axis

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2015 Dec 15

PMID 26662313

Citations 26

Authors

Sumei Zhou

Qidi Huang

Shurong Zheng

Kuailu Lin

Jie You

Xiaohua Zhang

Affiliations

Soon will be listed here.

Abstract

MicroRNA-27a (miR-27a) has been reported to be an onco-microRNA in multiple cancers promoting tumor growth and metastasis, but the role of miR-27a in regulating the cancer sensitivity to chemotherapy remains unknown. In this study, upregulation of miR-27a was validated by real-time PCR analysis in breast cancer (BC) cell lines and samples of BC patients. A negative correlation between miR-27a and bak was also observed in normal breast epithelial cell line MCF-10A and BC cell lines, suggesting that the bak is the potential target of miR-27a. miR-27a could modulate the growth and metastasis of BC cells. More importantly, we found that knockdown of miR-27a by the specific inhibitors significantly increased the sensitivity of T-47D cells to cisplatin (CDDP) treatment. After further investigation, we indicated that the knockdown of miR-27a promoted the apoptosis via mitochondrial pathway in T-47D cells treated with CDDP, depending on the BAK-second mitochondria-derived activator of caspase/direct IAP binding protein with low pI (SMAC/DIABLO)-X-linked inhibitor of apoptosis (XIAP) axis. Interestingly, we found that the sensitivity of T-47D cells to some other chemotherapeutic agents (5-fluorouracil, doxorubicin, and tumor necrosis factor-related apoptosis-inducing ligand) was also regulated by miR-27a. These findings improve our understanding of the role of miR-27a in breast cancer and might provide a novel strategy for cancer therapy.

Citing Articles

Molecular Biology of Cancer-Interplay of Malignant Cells with Emerging Therapies.

Boussios S, Sheriff M, Ovsepian S Int J Mol Sci. 2024; 25(23).

PMID: 39684799 PMC: 11642048. DOI: 10.3390/ijms252313090.

miRNAs in the Box: Potential Diagnostic Role for Extracellular Vesicle-Packaged miRNA-27a and miRNA-128 in Breast Cancer.

Giordano C, Accattatis F, Gelsomino L, Del Console P, Gyorffy B, Giuliano M Int J Mol Sci. 2023; 24(21).

PMID: 37958677 PMC: 10649351. DOI: 10.3390/ijms242115695.

Robust Identification of Differential Gene Expression Patterns from Multiple Transcriptomics Datasets for Early Diagnosis, Prognosis, and Therapies for Breast Cancer.

Tuly K, Hossen M, Islam M, Kibria M, Alam M, Harun-Or-Roshid M Medicina (Kaunas). 2023; 59(10).

PMID: 37893423 PMC: 10608013. DOI: 10.3390/medicina59101705.

Differential miRNA expression of hypoxic MCF7 and PANC-1 cells.

Al-Sisan S, Zihlif M, Hammad H Front Endocrinol (Lausanne). 2023; 14:1110743.

PMID: 37583428 PMC: 10424510. DOI: 10.3389/fendo.2023.1110743.

MiRNAs Action and Impact on Mitochondria Function, Metabolic Reprogramming and Chemoresistance of Cancer Cells: A Systematic Review.

Rosolen D, Nunes-Souza E, Marchi R, Tofolo M, Antunes V, Berti F Biomedicines. 2023; 11(3).

PMID: 36979672 PMC: 10045760. DOI: 10.3390/biomedicines11030693.

References

He H, Tian W, Chen H, Jiang K . MiR-944 functions as a novel oncogene and regulates the chemoresistance in breast cancer. Tumour Biol. 2015; 37(2):1599-607. DOI: 10.1007/s13277-015-3844-x. View

Tang W, Zhu J, Su S, Wu W, Liu Q, Su F . MiR-27 as a prognostic marker for breast cancer progression and patient survival. PLoS One. 2012; 7(12):e51702. PMC: 3519894. DOI: 10.1371/journal.pone.0051702. View

Yamamoto K, Ito S, Hanafusa H, Shimizu K, Ouchida M . Uncovering Direct Targets of MiR-19a Involved in Lung Cancer Progression. PLoS One. 2015; 10(9):e0137887. PMC: 4569347. DOI: 10.1371/journal.pone.0137887. View

Fang Z, Du R, Edwards A, Flemington E, Zhang K . The sequence structures of human microRNA molecules and their implications. PLoS One. 2013; 8(1):e54215. PMC: 3548844. DOI: 10.1371/journal.pone.0054215. View

Yin W, Nie Y, Zhang Z, Xie L, He X . miR-193b acts as a cisplatin sensitizer via the caspase-3-dependent pathway in HCC chemotherapy. Oncol Rep. 2015; 34(1):368-74. DOI: 10.3892/or.2015.3996. View

Hamacher-Brady A, Brady N . Bax/Bak-dependent, Drp1-independent Targeting of X-linked Inhibitor of Apoptosis Protein (XIAP) into Inner Mitochondrial Compartments Counteracts Smac/DIABLO-dependent Effector Caspase Activation. J Biol Chem. 2015; 290(36):22005-18. PMC: 4571954. DOI: 10.1074/jbc.M115.643064. View

Chen X, Liu J, Feng W, Wu X, Chen S . MiR-125b protects against ethanol-induced apoptosis in neural crest cells and mouse embryos by targeting Bak 1 and PUMA. Exp Neurol. 2015; 271:104-11. PMC: 4586365. DOI: 10.1016/j.expneurol.2015.04.026. View

Zhang Z, Li Y, Wang H, Fu S, Wang X, Zeng M . Knockdown of miR-214 promotes apoptosis and inhibits cell proliferation in nasopharyngeal carcinoma. PLoS One. 2014; 9(1):e86149. PMC: 3897649. DOI: 10.1371/journal.pone.0086149. View

Amankwatia E, Chakravarty P, Carey F, Weidlich S, Steele R, Munro A . MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms. Br J Cancer. 2015; 112(9):1480-90. PMC: 4453675. DOI: 10.1038/bjc.2015.125. View

10.

Sapio L, Sorvillo L, Illiano M, Chiosi E, Spina A, Naviglio S . Inorganic Phosphate Prevents Erk1/2 and Stat3 Activation and Improves Sensitivity to Doxorubicin of MDA-MB-231 Breast Cancer Cells. Molecules. 2015; 20(9):15910-28. PMC: 6332303. DOI: 10.3390/molecules200915910. View

11.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

12.

Li L, Luo J, Wang B, Wang D, Xie X, Yuan L . Microrna-124 targets flotillin-1 to regulate proliferation and migration in breast cancer. Mol Cancer. 2013; 12:163. PMC: 4029407. DOI: 10.1186/1476-4598-12-163. View

13.

Zhou H, Forveille S, Sauvat A, Sica V, Izzo V, Durand S . The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization. Oncotarget. 2015; 6(29):26599-614. PMC: 4694939. DOI: 10.18632/oncotarget.5613. View

14.

Li S, Li J, Fei B, Shao D, Pan Y, Mo Z . MiR-27a promotes hepatocellular carcinoma cell proliferation through suppression of its target gene peroxisome proliferator-activated receptor γ. Chin Med J (Engl). 2015; 128(7):941-7. PMC: 4834012. DOI: 10.4103/0366-6999.154302. View

15.

He Y, Wang J, Wang J, Yung V, Hsu E, Li A . MicroRNA-135b regulates apoptosis and chemoresistance in colorectal cancer by targeting large tumor suppressor kinase 2. Am J Cancer Res. 2015; 5(4):1382-95. PMC: 4473317. View

16.

Ye X, Zhang C, Chen Y, Zhou T . Upregulation of Acetylcholinesterase Mediated by p53 Contributes to Cisplatin-Induced Apoptosis in Human Breast Cancer Cell. J Cancer. 2015; 6(1):48-53. PMC: 4278914. DOI: 10.7150/jca.10521. View

17.

Leanza L, Venturini E, Kadow S, Carpinteiro A, Gulbins E, Becker K . Targeting a mitochondrial potassium channel to fight cancer. Cell Calcium. 2014; 58(1):131-8. DOI: 10.1016/j.ceca.2014.09.006. View

18.

Leisching G, Loos B, Botha M, Engelbrecht A . Bcl-2 confers survival in cisplatin treated cervical cancer cells: circumventing cisplatin dose-dependent toxicity and resistance. J Transl Med. 2015; 13:328. PMC: 4608303. DOI: 10.1186/s12967-015-0689-4. View

19.

Konac E, Varol N, Kiliccioglu I, Bilen C . Synergistic effects of cisplatin and proteasome inhibitor bortezomib on human bladder cancer cells. Oncol Lett. 2015; 10(1):560-564. PMC: 4487089. DOI: 10.3892/ol.2015.3250. View

20.

de Almagro M, Vucic D . The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy. Exp Oncol. 2012; 34(3):200-11. View